PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1265-1271

  Blykers, Anneleen ^a   Schoonooghe, Steve ^a,b   Xavier, Catarina ^a   D'Hoe, Kevin ^a,b   Laoui, Damya ^a,b   D'Huyvetter, Matthias ^a   Vaneycken, Ilse ^a,c   Cleeren, Frederik ^d   Bormans, Guy ^d   Heemskerk, Johannes ^a,c   Raes, Geert ^a,b   De Baetselier, Patrick ^a,b   Lahoutte, Tony ^a,c   Devoogdt, Nick ^a   Van Ginderachter, Jo A ^a,b   Caveliers, Vicky ^a,c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

18F; Camelid singledomain antibody fragment (sdAb); Macrophage mannose receptor (MMR); PET; Tumor microenvironment

Indexed keywords

CHEMOKINE RECEPTOR CCR2; FLUOROBENZOATE F 18; MANNOSE RECEPTOR; NANOBODY; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; FLUORINE; FLUOROBENZENE; FLUOROBENZOTEPA; LECTIN; MANNOSE BINDING LECTIN; TEPA;

ALPACA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CAMELID; CANCER GROWTH; CANCER PROGNOSIS; CELL POPULATION; CONTROLLED STUDY; CROSS REACTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; LEWIS CARCINOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DEFICIENCY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOCHEMISTRY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; AUTORADIOGRAPHY; C57BL MOUSE; CHEMISTRY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; NEOPLASM; NEW WORLD CAMELID; PH; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; CAMELIDS, NEW WORLD; FLUORINE RADIOISOTOPES; FLUOROBENZENES; HUMANS; HYDROGEN-ION CONCENTRATION; LECTINS, C-TYPE; MACROPHAGES; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; SINGLE-DOMAIN ANTIBODIES; TISSUE DISTRIBUTION; TRIETHYLENEPHOSPHORAMIDE;

EID: 84938883713     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.156828     Document Type: Article

References (32)

1. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor micro-environments. Cancer Res. 2006;66:605-612.
2. Allavena P, Sica A, Solinas G, Chiara Porta C, Mantovani A. The inflammatory microenvironment in tumor progression: the role of tumor-associated macro-phages. Crit Rev Oncol Hematol. 2008;66:1-9.
3. Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) Monocytes. Cancer Res. 2010;70:5728-5739.
4. Laoui D, Van Overmeire E, Movahedi K, et al. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology. 2011;216:1192-1202.
5. Laoui D, Van Overmeire E, Di Conza G, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 2014;74:24-30.
6. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14-20.
7. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally-occurring antibodies devoid of light-chains. Nature. 1993;363:446-448.
8. Schoonooghe S, Laoui D, Van Ginderachter JA, et al. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissue in inflammatory disease and cancer. Immunobiology. 2012;217:1266-1272.
9. De Groeve K, Deschacht N, De Koninck C, et al. Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med. 2010;51:782-789.
10. Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72:4165-4177.
11. Broisat A, Hernot S, Toczek J, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res. 2012;110: 927-937.
12. 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008; 47:8998-9033.
13. TM synthesizer. Mol Imaging Biol. 2011;13:1088-1095.
14. 18F]SFB) for protein labeling. J Labelled Comp Radiopharm. 2008;51:68-71.
15. Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G, Muyldermans S. Generation of single domain antibody fragments derived from camel-ids and generation of manifold constructs. Methods Mol Biol. 2012;907:145-176.
16. Conrath KE, Lauwereys M, Galleni M, et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother. 2001;45:2807-2812.
17. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25: 2433-2446.
18. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49:788-795.
19. 99mTc: a practical guide. Methods Mol Biol. 2012;911:485-490.
20. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313: 1960-1964.
21. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
22. De Vos J, Devoogdt N, Lahoutte T, Muyldermans S. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin Biol Ther. 2013;13: 1149-1160.
23. Ackermann U, Yeoh SD, Sachinidis JI, Poniger SS, Scott AM, Tochon-Danguy HJ. A simplified protocol for the automated production of succinimidyl 4-[F-18] fluorobenzoate on an IBA Synthera module. J Labelled Comp Radio-pharm. 2011;54:671-673.
24. Olafsen T, Sirk SJ, Olma S, Shen CKF, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 2012;33:669-677.
25. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med. 2007;48:304-310.
26. 18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med. 2012;53:679-686.
27. 18F-labeled phos-phoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med. 2009;50:2042-2048.
28. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
29. 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography. Nucl Med Biol. 2008;35: 725-731.
30. 18F]-SFB). Amino Acids. 2009;36: 283-295.
31. 18F-4-fluorobenzaldehyde. Bioconjug Chem. 2014;25:82-92.
32. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65:139-147.